Form 4: Crinetics Pharmaceuticals Director Rogerio Vivaldi Coelho Receives Significant Equity Grants

Crinetics Pharmaceuticals, Inc. Director Rogerio Vivaldi Coelho was granted 6,900 restricted stock units and 10,350 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Rogerio Vivaldi Coelho, a Director of Crinetics Pharmaceuticals, Inc. (CRNX), acquired 6,900 shares of Common Stock in the form of restricted stock units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0 and will vest 100% on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to continued service.
• Following this transaction, Mr. Coelho beneficially owns 21,300 shares of Common Stock directly.
• Additionally, Mr. Coelho was granted 10,350 stock options with an exercise price of $32.33 on June 11, 2025.
• These stock options were granted at a price of $0 and will vest and become exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to continued service.
• The stock options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Coelho beneficially owns 10,350 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports routine equity grants to a director, which is a positive for aligning management interests with shareholders. There are no negative or unexpected elements.

Positives

• The grant of restricted stock units and stock options to Director Rogerio Vivaldi Coelho aligns his financial interests directly with the long-term performance and shareholder value of Crinetics Pharmaceuticals, Inc.
• Equity compensation is a standard practice to incentivize directors and retain talent, demonstrating commitment from the board member.

Future Outlook

The restricted stock units and stock options are subject to vesting conditions, which require the director's continued service on the board until the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. The stock options have an expiration date of June 11, 2035.

Industry Context

Equity grants, such as restricted stock units and stock options, are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice is designed to align the interests of company leadership with those of shareholders, encouraging long-term value creation.

Comparison to Industry Standards

• The granting of equity compensation to directors is a standard practice across the biotechnology and pharmaceutical sectors, aiming to align director incentives with shareholder returns.
• While specific grant sizes vary based on company size, director responsibilities, and compensation policies, the structure of RSUs and stock options with vesting conditions tied to continued service is typical for director compensation packages in publicly traded companies.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The restricted stock units and stock options will vest on the earlier of the first anniversary of the grant date (June 11, 2026) or the next annual meeting of Crinetics Pharmaceuticals, Inc. stockholders, subject to continued service.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership